<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="23359">Colchicine</z:chebi> is the treatment of choice in familial Mediterranean <z:hpo ids='HP_0001945'>fever</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>) for the prevention of both attacks and secondary <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The overall nonresponder rate is about 5-10% </plain></SENT>
<SENT sid="2" pm="."><plain>Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [<z:hpo ids='HP_0011010'>chronic</z:hpo> infantile neurological cutaneous and articular (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>) syndrome] and other recurrent hereditary periodic <z:hpo ids='HP_0001945'>fevers</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Pyrin--the protein involved in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>--has a role in activating the proinflammatory cytokine interleukin (IL)-1beta </plain></SENT>
<SENT sid="4" pm="."><plain>We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to <z:chebi fb="0" ids="23359">colchicine</z:chebi> in controlling the febrile attacks and <z:hpo ids='HP_0011009'>acute</z:hpo> phase response in an adolescent with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e> resistant to <z:chebi fb="0" ids="23359">colchicine</z:chebi> </plain></SENT>
</text></document>